Although the precise mechanisms underlying the role of the hypocretin system in MDD remain unclear, emerging pharmacological evidence points to the potential utility of hypocretin receptor antagonists in alleviating depressive symptoms. The gene discussed is HCRT; the disease is major depressive disorder.